Physician profile
Christopher S Baltzell
NPI 1144776998
$3,035.92
in general payments reported to CMS, 2019-2025
29 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $641 · 2023: $667 · 2024: $811 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.23 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $256.85 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $241.34 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.95 | 2021-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $141.22 | 2023-2025 | Gemtesa |
| Pfizer INC. | $132.82 | 2021-2025 | |
| Amgen INC. | $111.05 | 2021-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $94.88 | 2022-2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.01 | 2021-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $89.50 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $79.12 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.46 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.79 | 2022 | |
| Mylan Specialty L.P. | $58.11 | 2022-2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $54.64 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.28 | 2022-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $51.72 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $45.11 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $40.22 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $33.48 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $27.70 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $23.59 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.96 | 2021 | |
| Lundbeck LLC | $16.85 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $16.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.00 | 2021 | |
| Amarin Pharma, INC. | $15.72 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baltzell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.